
Novavax Inc
NVAX · NASDAQ · Healthcare / Biotechnology
8.53USD-0.23 (-2.63%)
Price History
Full chartMarket Stats
Previous Close8.76
Open8.77
Day Range8.35 – 8.79
52-Week Range6.20 – 13.39
Volume4.64M
Market Cap1.70B
P/E (TTM)0.00
Forward P/E2.58
EPS-1.63
Dividend Yield0.00%
Beta2.44
50-Day Avg10.39
200-Day Avg9.28
About
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Company Details
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. John Charles Jacobs M.B.A.
- Employees749
- Headquarters21 Firstfield Road, Gaithersburg, MD, United States, 20878, USA
- Websitehttps://www.novavax.com
Leadership
- Mr. John Charles Jacobs M.B.A.President, CEO & Director · b. 1967
- Mr. James Patrick Kelly C.F.A.Executive VP, CFO & Treasurer · b. 1966
- Mr. Mark J. Casey Esq., J.D.Executive VP, Chief Legal Officer & Corporate Secretary · b. 1963
- Ms. Elaine O'HaraExecutive VP & Chief Strategy Officer · b. 1968
- Mr. Richard P. CrowleyExecutive VP & COO · b. 1957
- Ms. Naina ZamanDirector of Investor Relations
- Mr. Troy Morgan Esq., J.D.Senior VP, Deputy General Counsel & Chief Compliance Officer · b. 1971
- Ms. Erika S. TrahanAssociate Director of Investor & Public Relations
- Mr. Ian J. WatkinsExecutive VP & Chief Human Resources Officer · b. 1963
- Ms. Silvia Taylor M.B.A.Executive VP, Chief Corporate Affairs Officer & Head of Novavax Sweden
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Market Cap1.70B
Enterprise Value1.23B
Trailing P/E0.00
Forward P/E2.58
PEG Ratio1.32
Price / Sales4.11
Price / Book41.23
EPS-1.63
Book Value-1.16
Revenue (TTM)413.80M
Gross Profit (TTM)-10.58M
EBITDA-101.55M
Profit Margin-59.87%
Operating Margin-89.61%
Return on Equity-898.20%
Return on Assets-6.51%
Shares Outstanding164.95M
Shares Float146.21M
Beta2.44
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%
Analyst Ratings
Buy
Based on 9 analystsTarget 14.22
- Strong Buy5
- Hold1
- Sell2
- Strong Sell1
Ownership Breakdown
- Institutions
- 66.64%
- Insiders
- 5.05%
- Retail / Other
- 28.31%
Top Institutional Holders
- BlackRock Inc13.95M8.46%
- Shah Capital Management12.17M7.38%
- State Street Corp11.74M7.12%
- Vanguard Portfolio Management, LLC7.61M4.61%
- Vanguard Capital Management, LLC7.26M4.40%
- Sanofi6.88M4.17%
- D. E. Shaw & Co LP5.65M3.43%
- Geode Capital Management, LLC4.21M2.55%
- Two Sigma Investments LLC4.09M2.48%
- Coatue Management LLC3.84M2.33%
- Bank of America Corp3.42M2.07%
- The Goldman Sachs Group Inc3.01M1.82%
- UBS Group AG1.87M1.13%
- Millennium Management LLC1.77M1.07%
- Citadel Advisors Llc1.70M1.03%
Top Fund Holders
- Vanguard MStar Total Stk Mkt Idx Invest5.20M3.15%
- State Street® SPDR® S&P® Biotech ETF4.63M2.81%
- iShares Russell 2000 ETF3.97M2.41%
- Vanguard Small Cap Index3.71M2.25%
- Vanguard MStar Small Cap Growth Indx Inv2.07M1.25%
Stock Splits
- May 10, 20191:20